Pancreatic Cancer Research

ResearcherCenter for Biomedical Research of La RiojaActive in the last 2 years

Alfredo Martı́nez

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4882-4044; OpenAlex author ID A5011115344. Sources: OpenAlex.

Their work

Papers
5 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
4
Papers, trials and grants by year

2024: 4 papers · 2025: none · 2026: 1 paper

Papers 5

  1. Optimized chemotherapy sequence for metastatic pancreatic ductal adenocarcinoma patients: FOLFIRINOX followed by Gemcitabine plus nab-paclitaxel. Last author DOI 10.1186/s12885-026-16391-7↗
  2. Detection of Tumor-Associated Autoantibodies in the Sera of Pancreatic Cancer Patients Using Engineered MUC1 Glycopeptide Nanoparticle Probes. Co-author DOI 10.1002/anie.202407131↗
  3. Highly sensitive serum volatolomic biomarkers for pancreatic cancer diagnosis. Last author DOI 10.1016/j.cca.2024.117895↗
  4. New model to predict survival in advanced pancreatic ductal adenocarcinoma patients by measuring GGT and LDH levels and monocyte count. Last author DOI 10.3389/fonc.2024.1411096↗
  5. Corrigendum: New model to predict survival in advanced pancreatic ductal adenocarcinoma patients by measuring GGT and LDH levels and monocyte count. Last author DOI 10.3389/fonc.2024.1540165↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Rocío del Campo-Pedrosa · 3 shared papers, 2024–2026 · strength 1.05
  2. María Pilar Santamaría Martínez · 2 shared papers, 2024 · strength 0.47
  3. Francisco Corzana · 1 shared paper, 2024 · strength 0.16
  4. Roberto Fiammengo · 1 shared paper, 2024 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.